Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
15.70
-0.42 (-2.61%)
At close: Oct 10, 2025, 4:00 PM EDT
15.50
-0.20 (-1.27%)
After-hours: Oct 10, 2025, 6:54 PM EDT
Keros Therapeutics Employees
Keros Therapeutics had 169 employees as of December 31, 2024. The number of employees increased by 33 or 24.26% compared to the previous year.
Employees
169
Change (1Y)
33
Growth (1Y)
24.26%
Revenue / Employee
$1,377,775
Profits / Employee
$111,083
Market Cap
637.66M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 169 | 33 | 24.26% |
| Dec 31, 2023 | 136 | 31 | 29.52% |
| Dec 31, 2022 | 105 | 45 | 75.00% |
| Dec 31, 2021 | 60 | 25 | 71.43% |
| Dec 31, 2020 | 35 | 12 | 52.17% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KROS News
- 4 weeks ago - Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting - GlobeNewsWire
- 6 weeks ago - Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - GlobeNewsWire
- 7 weeks ago - ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment - PRNewsWire
- 7 weeks ago - Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy - GlobeNewsWire
- 2 months ago - Keros to Exclusively Prioritize the Clinical Advancement of KER-065 - GlobeNewsWire
- 2 months ago - Keros Therapeutics Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept - GlobeNewsWire
- 4 months ago - ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal - PRNewsWire